Table 2 DXR-MCI loss in the methotrexate plus adalimumab group and the MTX group stratified for disease activity measured by DAS28
Adalimumab + methotrexate | Methotrexate | |||
|---|---|---|---|---|
N = 214 | Median (mean) % DXR-MCI change | N = 188 | Median (mean) % DXR-MCI change | |
Remission DAS28 ≤2.60 | 118 | -2.43 (-2.73) | 53 | -2.15 (-3.03) |
Low disease activity DAS28 2.61-3.20 | 36 | -1.98 (-2.59) | 30 | -2.09 (-2.90) |
Moderate disease activity DAS 28 3.21-5.10 | 51 | -2.01 (-3.17) | 81 | -3.33 (-4.65) |
High disease activity DAS28> 5.10 | 9 | -1.63 (-2.72) | 24 | -3.02 (-4.64) |